Irulya Therapeutics (IRLA) closed at $32.83 on October 22, 2026, down 5.3% from the previous close, on volume of 165,108 shares (30-day average 97,481).
Data as of October 22, 2026.
IRulya updates rare pulmonary LAM-001 development strategy
TipRanks (Mon, 19-Oct 9:23 AM ET)
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
Globe Newswire (Thu, 15-Oct 8:00 AM ET)
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
Irulya Therapeutics trades on the NASDAQ stock market under the symbol IRLA.
As of October 22, 2026, IRLA stock price declined to $32.83 with 165,108 million shares trading.
IRLA has a market cap of $33.39 million. This is considered a Sub-Micro Cap stock.
IRLA support price is $30.34 and resistance is $39.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRLA shares will trade within this expected range on the day.
